IBB iShares Biotechnology ETF
Bearish lean Confidence 0.36 Regime Mid-vol · at high
Maintain a medium-term bearish view on IBB, driven by non-price evidence from arc id=298: an increase in CMS documents related to drug pricing/pharmacy benefits (current count = 3) suggests regulatory/price downside risks; coupled with rising risk-free rates (recent rise in US Treasury yields) and substantial net redemptions starting from 2026-10-13 (-2.01% AUM, approximately -$209M), which directly pressure valuation and liquidity. Note that some information is already factored into the price (price_in=True), and this arc is in its nascent stage with days_since_event=11, thus limiting confidence.
30-day verdict history
| Date | Direction | Confidence | Thesis |
|---|---|---|---|
| 2026-10-22 | Bearish lean | 0.36 | Maintain a medium-term bearish view on IBB, driven by non-price evidence from arc id=298: an increase in CMS documents related to drug pricing/pharmacy benefits (current count = 3) suggests regulatory/price downside risks; coupled with rising risk-free rates (recent rise in US Treasury yields) and substantial net redemptions starting from 2026-10-13 (-2.01% AUM, approximately -$209M), which directly pressure valuation and liquidity. Note that some information is already factored into the price (price_in=True), and this arc is in its nascent stage with days_since_event=11, thus limiting confidence. |
| 2026-10-21 | Bearish lean | 0.40 | Maintain a medium-term bearish view on IBB, primarily driven by non-price evidence from arc id=298. The arc indicates an increase in CMS documents related to drug pricing/pharmacy benefits to 3 in the past 30 days (raising regulatory/price downside risks), while rising risk-free rates and approximately -2.01% net redemptions since 2026-10-13 suggest pressure on valuation and liquidity, all of which are negative fundamentals outside of price action. Note that some risks have been factored into the market (price_in=True), and the event is about 10.1 days away with a nascent status, thus confidence is moderately limited to low-medium. |
| 2026-10-20 | Bearish lean | 0.40 | Maintain a lean negative stance on IBB on a medium-term basis. The primary driver is arc id=298: the count of CMS documents related to drug pricing/healthcare insurance in the past 30 days has risen (current value = 3), indicating accumulating regulatory/pricing pressure; meanwhile, the rise in risk-free rates increases the discount rate for biopharmaceuticals, and since October 13, 2026, there has been approximately -2.01% AUM net redemptions from the fund, signaling pressure on liquidity—these are non-price negative indicators. Note that prices have already partially reflected some of these risks (price_in_excess marked as True in arc), so confidence is moderately constrained. |
| 2026-10-19 | Bearish lean | 0.38 | Shifted from a previously 'mixed' outlook to lean negative on IBB for the intermediate term, as the arc id=622 (biosimilar_patent_cliff_2026_2028) that had provided upward momentum or offsetting bullishness has been excluded/closed, removing the main counter-price evidence. The remaining dominant arc id=298 continues to provide negative non-price arguments: with CMS/medicare-related document counts at 2 in the past 30 days and persistently high risk-free rates increasing the discounting pressure on biopharmaceutical valuations. Meanwhile, positive fund flows (net redemptions positive over the past 5 and 30 days) and elevated implied volatility pose friction to short execution, thus maintaining a low-to-medium level of confidence. |
| 2026-10-18 | Mixed | 0.40 | Maintain a mixed stance: the two dominant arcs offset each other in non-price evidence. Non-price driver id=298 (30-day count of CMS/healthcare-related documents = 2 and upward movement in risk-free rates) creates a structural downward pressure on biopharma valuations; but non-price evidence from report id=622 (recent net issuance/inflows, significant short positions, and high implied volatility) limits the bear case and introduces upward friction. Given that id=622 is somewhat stale (days_since_event = 15.1) and id=298 has just crossed the |
| 2026-10-17 | Mixed | 0.40 | Maintain mixed. The non-price-driven bearish side comes from id=298: CMS/healthcare-related document counts in the past 30 days = 2, and the upward movement of risk-free rates as shown in the quant block, which creates a structural downward pressure on long-duration biotech valuations. This is offset by non-price evidence from reports id=622 and id=620 – recent net creation/inflows (positive for the past 5-30 days), high implied volatility at the option end, and significant short positions/short squeeze risk, which limit the execution of shorts marginally. Additionally, note that id=622 is marked as price_in, indicating that some expectations have been absorbed by prices; given that all three arcs are nascent and evidence offsets each other, maintain low to medium confidence. |
| 2026-10-16 | Mixed | 0.40 | Maintain mixed. The bearish side is driven by non-price evidence provided in id=298: CMS/medicare document counts over the past 30 days = 2 (ongoing regulatory uncertainty) and elevated Treasury bond yields at the quantitative level (quant block us10y ≈5.1–5.2%), which constitute a structural downside pressure on long-duration biopharmaceuticals. The bearish decline is checked by funding and positioning evidence from id=622 and id=620 reports—recent net creation/flows in reality (net redemptions over the past week and 30 days are positive), high implied volatility at the options end, and crowded short positions, which provide substantial support and weaken the bearish edge. Given that all three arcs are nascent and non-price confirming evidence is not yet sufficient, maintain mixed with low to medium confidence. |
| 2026-10-15 | Mixed | 0.40 | Maintain a mixed outlook. The non-price evidence for id=298 - with CMS/Medicare document counts over the past 30 days at 2 (indicating ongoing regulatory uncertainty) and rising US Treasury yields (increasing discount rates) - continues to pose a structural downside risk to IBB; but funding and positioning evidence from reports id=622 and id=620 (net creation/inflows starting from 2026-10-07, AUM climbing, and high IV and crowdedness in the options segment) provide substantial support for long positions and weaken bearish execution margins. All three arcs remain nascent/low confidence and no new one-sided, confirming non-price evidence has emerged, thus maintaining a mixed outlook with confidence around 0.40. |
| 2026-10-14 | Mixed | 0.40 | Maintain a mixed outlook. Non-price evidence id=298 (30-day count of CMS/Medicare documents = 2, and increased Treasury yields raising discount rates) continues to pose a structural downside risk channel for IBB; but non-price evidence id=620 (supplemented by id=622) on funding and positioning – net creation +$320M since 2026-10-07 (+2.97% AUM, 30d +3.38% AUM), with front-end IV at high levels and calls > puts – provides substantial support to the long side and weakens the bear case marginally. Given that these core non-price signals largely offset each other and are mostly nascent/low-level indicators, maintain a mixed outlook with confidence similar to before (≈0.40). |
| 2026-10-13 | Mixed | 0.40 | Overall, it is a mixed call: The non-price evidence provided by id=298 (3 CMS/medicare-related documents in the past 30 days and the suppression of long-duration biopharmaceutical valuations due to high interest rates) still points to structural downside risks; however, the latest non-price signal from id=620 shows a net creation of +3.24% AUM over the past 5 days, indicating a return of funds and supportive demand that significantly offsets immediate bearish reasons. The option volatility (IV rank ~93%) is at high levels, indicating continued uncertainty and protective demand, thus maintaining a neutral stance rather than a one-sided bias. The non-price evidence (CMS documents and fund flows) forms the main basis for this conclusion, with price momentum not being the decisive driver. |
| 2026-10-12 | Bearish lean | 0.52 | Maintain a bearish stance on IBB, primarily based on non-price evidence from ID=298: CMS/medicare-related drug-pricing documents have been ongoing for the past 30 days, and real net redemptions of -$328M were observed starting from 2026-10-02, indicating a risk channel of fund withdrawal and policy/pricing downside. Additional evidence of interest rate pressure on high-duration biopharmaceutical valuations supports directional concerns for the fundamentals. ID=622 adds structural drug price/biosimilar risks but its quantitative snapshot contradicts the bearish argument (excess_sigma=+0.40 inconsistent with downward expectations) and FINRA short positions have declined, reducing operational confidence immediately. The option side's IV is at a high level (IV rank ~93%) indicating high uncertainty and that volatility premium has been factored in, hence maintaining a bearish stance but only moderately confident; the conclusion is based on non-price evidence with ID=622’s quantitative contradiction noted as a limiting factor. |
| 2026-10-11 | Bearish lean | 0.50 | Maintain a bearish stance on IBB, primarily based on non-price evidence from id=298 (US healthcare political cycle): CMS/medicare-related documents have been ongoing for the past 30 days and there has been net redemptions of -$328M since 2026-10-02, indicating real fund outflows with political/regulatory risk channels. id=622 (biosimilar patent cliff) adds to the logic of structural pricing downside, but its quantitative snapshot shows excess_sigma=+0.40 which contradicts the bearish argument and FINRA short positions have declined, weakening the immediacy of this arc's execution; id=620 limits a strong consensus with a hedging/neutral stance. The conclusion is driven by non-price evidence (regulatory documents, net redemptions, interest rate pressure on long-duration sectors) and there are no single confirmatory events or widespread market pricing-in. |
| 2026-10-10 | Bearish lean | 0.50 | Maintain a bearish stance on IBB, primarily supported by id=298 (ongoing CMS/Medicare-related documents + net redemptions of -$328M starting from 2026-10-02) and id=622 (structural pricing downside risk from biosimilar/patent cliff with continued net outflows). Note that id=622 presents a contradiction in price signals to its bearish argument (excess_sigma=+0.40, indicating relative prices have not weakened), and FINRA short positions have declined (11.56M, -5.8%), suggesting reduced pressure from both shorts and capital flows, which limits the upper bound of confidence. Given that all arcs are nascent and there is no single confirmatory event, maintain a bearish stance but with low to medium confidence. |
| 2026-10-09 | Bearish lean | 0.52 | Maintain a bearish stance on IBB, primarily driven by id=298 (price/reimbursement tightening risks from the latest CMS/Medicare Advantage documents, and short-term net outflows and rising option IV and short positions) and id=622 (ongoing net outflows and increased short positions over recent days provide non-price evidence of valuation and demand-side concerns for the sector). Both provide empirical reasons against a price decline. However, it is noted that excess_sigma=+1.34 in the quant snapshot for id=622 contradicts its bearish argument, reducing confidence. Additionally, high IV levels and short squeeze (increased short_interest and DTC days-to-cover=7.85) will amplify volatility and limit one-sided downside, leading to a moderately low-confidence bearish conclusion. |
| 2026-10-08 | Bearish lean | 0.48 | I am inclined to short IBB: the driving non-price evidence comes from id=620 (GLP-1 band), which shows net redemptions of -$412M (-3.96% AUM) since 2026-10-01, pointing to weak demand; meanwhile, id=622 (biosimilar ) indicates an increase in short positions (short_interest +11.7%, DTC 7.85) with CMS/pricing regulatory documents supporting sector-wide downside risks. This non-price evidence from liquidity and positioning/regulatory perspectives constitutes negative fundamental reasons for the short to medium term, rather than purely price momentum-driven. Given that option IV is at a high level and there is crowding in the shorts with some recent declines already priced-in, I maintain my confidence at a moderate-low level and caution against the risk of a squeeze and increased volatility. |
| 2026-10-07 | Neutral | 0.35 | Maintain Neutral: The latest two arcs offset each other on non-price evidence, with no clear unidirectional fundamental driver yet. ID=620 indicates net inflows into the sector (net inflow +1.09%/+1.18% AUM over the past 5/30 days) and overall option IV remains at a high level (IV rank 98%), suggesting pricing activity and speculative intent, but not necessarily bearish buying. ID=622 shows stronger protective signals with crowded short positions (IV rank 95%, put IV>call IV, short interest +11.7%, DTC 7.85), with non-price quantitative evidence offsetting each other and price_in=None, thus maintaining a neutral stance in the short term. |
| 2026-10-06 | Neutral | 0.35 | Maintain neutral stance. Both arcs (id 620 GLP-1/obesity and diabetes theme and id 622 biosimilar patent cliff) are nascent or contested, with non-price evidence canceling each other out: on one hand, there is still a slight net inflow in terms of assets under management (AUM ≈ $10.4B, inflows over the past 30/90 days); on the other hand, option metrics indicate high implied volatility and put bias (IV rank 95%, put IV > call IV, increase in put-call skew) with rising short interest (+11.7%, DTC ≈ 7.85), suggesting downward pressure and hedging demand. The event is recent (≤7 days) and price_in=None, so maintain a neutral stance with low confidence and no directional bias. |
| 2026-10-05 | Neutral | 0.35 | The non-price evidence from the two arcs cancels each other out: Arc 620 (GLP-1/obesity and diabetes theme) provides supportive evidence of net inflows in terms of funding (IBB AUM at $10.6B, with recent net inflows over the past 30/90 days) and macro liquidity conditions; while Arc 622 points to downside hedging through option market sentiment bias towards puts (put-call skew rising, put IV > call IV) and increased short positions, indicating clear demand for downside hedging. Both arcs are nascent/contested, with recent events (within the last 7 days) that have not yet become confirmed/actionable, and price_in has not shown one-sided realization (flagged=False), thus a directional bias cannot be determined in the short to medium term. Maintain neutrality with low confidence. |
| 2026-10-04 | Neutral | 0.35 | Maintain Neutral Call: The two arcs offset each other. Arc 620 (GLP-1/Obesity and Diabetes theme) provides bullish non-price evidence—IBB has net inflows over the past 30/90 days, AUM growth, and positive Fed net liquidity supporting a medium-term risk asset exposure; but Arc 622 (Biologic Follow-Ons/Patent Cliff) points to clear negative non-price signals—the put-call skew is rising, short positions are increasing, and regulatory/pharmaceutical price documents pose downside hedging needs. Both are nascent/contested with no confirmed trigger events, and there is currently no independent non-price evidence that has been priced in (price_in not marked), so maintain a neutral stance with low confidence. |
| 2026-10-03 | Neutral | 0.35 | Two active arcs provide offsetting non-price evidence: arc 620 (GLP-1/Obesity and Diabetes theme) indicates a bullish stance on liquidity—IBB has seen significant net inflows in the past 30/90 days (+4.46%/+8.41% AUM), and federal net liquidity is positive, supporting exposure to medium-term risk assets; while arc 622 (Biologic Follow-Ons/Patent Cliff) highlights non-price signals pointing to downside tail risks—option put-call skew has risen, short positions have increased, and there are recent CMS/drug-pricing documents indicating regulatory/defensive hedging needs. Both are nascent/contested with no confirmed trigger events, so we maintain a neutral stance with low confidence (evidence is balanced, cannot be determined by price momentum alone). |
| 2026-08-15 | Neutral | 0.00 | No active arcs provided direction (all closed/contested or no arc coverage). |
| 2026-08-14 | Neutral | 0.05 | Maintain a neutral stance (no one-sided judgment). Driven by arc 298 (us_healthcare_political_cycle): About 13 days after the event, non-price quantitative evidence has not conveyed arbitration/regulatory news into a substantive impact on IBB — with net inflows over the past 30 days (fund_flow_30d_pct_aum=2.64%), net inflows in the last 5 days, a decrease in short interest, and low and non-amplifying implied volatility (iv_rank 16%), these signals refute the conclusion that the market has experienced large-scale exodus or systemic damage. The arc is in a decaying state with low self-confidence, so continue to maintain neutral; no non-price chain has been found that can quantify regulatory news into earnings/provision impacts or passive weight impacts. |
| 2026-08-13 | Neutral | 0.05 | Maintain neutral stance; the driver is arc 298 (us_healthcare_political_cycle), with non-price evidence insufficient to translate regulatory/arbitration news into a one-sided impact on IBB. This arc is decaying (days_since_event=12, weaken_streak=4) and shows no outflows of capital (net creation +$61M since 2026-07-27, inflows up 2.27% AUM in the past 30 days), with short interest slightly down to about 11.9M (days-to-cover=6.42). Option IV is at historical lows and has decreased over the last five days—these non-price signals contradict a direct equivalence of regulatory news to systematic downside for IBB. Given the lack of new quantifiable transmission channels and evidence tilting neutral, maintain low-confidence neutral judgment. |
| 2026-08-12 | Neutral | 0.05 | Maintain Neutral Stance: The driving force is arc 298 (us_healthcare_political_cycle), which does not provide a non-price channel for regulatory/arbitration news to be transmitted to IBB funding flows or earnings expectations. Instead, non-price evidence shows that funds have not been withdrawn (net creation of +$61M since 2026-07-27, inflows of +2.27% AUM in the past 30 days), short interest is approximately 11.9M, and days-to-cover is 6.42. Option IV is at historical lows and has been declining over the last five days, which constitutes a counter-argument to one-sided bearish views. The arc remains decaying (weaken_streak=4, days_since_event≈11), thus maintaining a low-confidence neutral judgment. |
| 2026-08-11 | Neutral | 0.05 | Maintain a neutral stance, with the driver still being arc 298 (us_healthcare_political_cycle). The arc indicates that despite regulatory/CMS-related reports, there is no direct non-price chain linking arbitration payouts/regulatory progress to IBB cash flows or earnings expectations; instead, non-price data (net creation of +$61M since 2026-07-27, a 2.27% AUM inflow in the past 30 days, short interest approximately 11.9M with days-to-cover=6.42, and option IV at historical lows) constitutes counter-evidence to one-sided bearish views. The arc is currently decaying (weaken_streak=4, days_since_event=10.1), thus lacking new actionable evidence to alter the previous neutral judgment. |
| 2026-08-10 | Neutral | 0.04 | Maintain a neutral stance, with drivers still centered on arc 298 (us_healthcare_political_cycle). The arc acknowledges the presence of regulatory downside news (WSJ and CMS/Medicare documents) but does not provide evidence to connect 'arbitration awards/regulatory progress -> direct non-price transmission to IBB cash flows or earnings expectations.' Instead, non-price data serves as a counter-argument against one-sided bearish views: net creation since 2026-07-27 of +$61M (near 30-day +2.27% AUM), short interest at 11.9M with days-to-cover=6.42, ATM IV at historical lows, and the arc is decaying (weaken_streak=4, days_since_event=8.9); price_in is not marked, so confidence remains low. |
| 2026-08-09 | Neutral | 0.03 | Maintain neutral, low confidence. Drivers remain for arc 298 (us_healthcare_political_cycle): this arc signals regulatory downside risks but lacks proof connecting 'arbitration awards -> direct non-price evidence of IBB funding/profitability' to the ETF level; instead, net creations in the past 30 days are +$144M (+1.54% AUM), short interest slightly decreased to 11.9M shares, days-to-cover=6.42, and option IV is at only the 31st percentile with skew not indicating a clear demand for downside protection; these non-price signals do not support a one-sided bearish view. The arc state is decaying and weaken_streak=4, and window returns have partially reflected regulatory concerns, thus maintaining neutrality and low confidence. |
| 2026-08-08 | Neutral | 0.05 | Maintain neutral, low confidence. Drivers remain as arc 298 (us_healthcare_political_cycle): while the arc suggests a possibility of regulatory easing, there is no proof connecting the arbitration payouts to direct non-price evidence for IBB funds/profits at the ETF level. Instead, non-price data (net creations over the past 30 days of +$144M, slightly reduced short positions to 11.9M, low option IV and no significant skew indicating minimal demand for downside protection) along with in-window excess returns of -2.72% suggest that concerns may have been partially priced in, but there is insufficient evidence currently supporting a one-sided conclusion, hence maintaining a neutral stance with low confidence. |
| 2026-08-07 | Neutral | 0.06 | Maintain neutral, low confidence. Driven by arc 298 (us_healthcare_political_cycle): The Wall Street Journal reports on arbitration payouts and recent CMS/Medicare documents do indeed suggest regulatory downside, but there is a lack of non-price evidence linking these events to the ETF level. Instead, net creations of IBB of +$144M in the past 30 days (+1.54% AUM) and a slight decrease in short interest along with low option IV indicate that funds and risk premiums have not provided non-price signals supporting a one-sided bearish stance; prices are already partially factoring in (window excess return -2.72%), thus it is not advisable to continue maintaining a bearish conclusion. |
| 2026-08-06 | Bearish lean | 0.12 | 维持对 IBB 在 1–3 个月内偏空，但置信较低。驱动仍是 arc 298（US Healthcare Political Cycle）：WSJ 关于联邦仲裁的大额赔付线索与近 30 日 CMS/Medicare 文件构成监管/支付端下行风险，但缺乏将这些事件直接连到 ETF 层面的确证。相反，非价格证据——近 30 日净创设 +1.54% AUM、空头持仓小幅下降与期权 IV 处于低位——抵消了单边看空论据；价格也已部分反映监管担忧，因此保持温和偏空并压低置信度。 |